Trial Profile
An impact of short transition/washout periods on imaging and clinical effectiveness outcomes of fingolimod after switching from natalizumab.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2016
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 10 May 2016 New trial record
- 21 Apr 2016 Results presented at the 68th Annual Meeting of the American Academy of Neurology